Tardive dystonia

Current Treatment Options in Neurology

Volumn 7, Issue 3, 2005, Pages 231-236

  Skidmore, Frank ^b   Reich, Stephen G ^a  

^a UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA TOCOPHEROL; AMITRIPTYLINE; ANTIDEPRESSANT AGENT; ANTIEMETIC AGENT; ATYPICAL ANTIPSYCHOTIC AGENT; BACLOFEN; BENZODIAZEPINE DERIVATIVE; BOTULINUM TOXIN; CALCIUM CHANNEL BLOCKING AGENT; CENTRAL DEPRESSANT AGENT; CHLORPROMAZINE; CHOLINERGIC RECEPTOR BLOCKING AGENT; CINNARIZINE; CLONAZEPAM; CLOZAPINE; DIGOXIN; DOPAMINE RECEPTOR BLOCKING AGENT; FLUNARIZINE; FLUPHENAZINE; HALOPERIDOL; LEVODOPA; LOXAPINE; METOCLOPRAMIDE; NEUROLEPTIC AGENT; OLANZAPINE; PERPHENAZINE; PIMOZIDE; PROCHLORPERAZINE; PROMETHAZINE; QUETIAPINE; RESERPINE; RISPERIDONE; TETRABENAZINE; THIORIDAZINE; TIOTIXENE; TRIHEXYPHENIDYL; ZIPRASIDONE;

ACUTE DRUG ADMINISTRATION; AKATHISIA; ANHIDROSIS; ANXIETY DISORDER; ARTICLE; ATAXIA; ATTENTION DEFICIT DISORDER; BODY WEIGHT DISORDER; CHOREA; CHRONIC DRUG ADMINISTRATION; CLINICAL TRIAL; COMORBIDITY; CONFUSION; CONSTIPATION; COST EFFECTIVENESS ANALYSIS; DELIRIUM; DEPRESSION; DIABETES MELLITUS; DIPLOPIA; DISABILITY; DISEASE CLASSIFICATION; DISEASE EXACERBATION; DISEASE SEVERITY; DISTRESS SYNDROME; DROWSINESS; DRUG CONTRAINDICATION; DRUG DOSE REGIMEN; DRUG EXPOSURE; DRUG INDUCED DISEASE; DRUG MECHANISM; DRUG POTENTIATION; DRUG SAFETY; DRUG WITHDRAWAL; DYSPHAGIA; DYSPHONIA; EARLY DIAGNOSIS; FLU LIKE SYNDROME; GILLES DE LA TOURETTE SYNDROME; GLAUCOMA; HALLUCINATION; HUMAN; HYPERGLYCEMIA; HYPERTHERMIA; HYPOTENSION; INSOMNIA; LEUKOCYTOSIS; LIVER TOXICITY; MEMORY DISORDER; MOTOR DYSFUNCTION; MUSCLE SPASM; MUSCLE WEAKNESS; MYOCLONUS; NEUROLEPTIC MALIGNANT SYNDROME; ORTHOSTATIC HYPOTENSION; PARKINSONISM; PHENOMENOLOGY; PTOSIS; RESTLESSNESS; RISK REDUCTION; SEDATION; SEIZURE; SOMNOLENCE; STEREOTYPY; SYMPTOMATOLOGY; TARDIVE DYSKINESIA; TARDIVE DYSTONIA; TREATMENT PLANNING; TREMOR; UNPLEASANT SENSATION; URINE RETENTION; VISUAL IMPAIRMENT; WEIGHT GAIN; XEROSTOMIA;

EID: 21244454497     PISSN: 10928480     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11940-005-0016-0     Document Type: Article

References (35)

1. Urhbrand O, Faurbye A: Reversible and irreversible dyskinesia after treatment with perphenazine, chlorpromazine, reserpine, ECT therapy. Psychopharmacologia 1960, 1:408-418.
2. Faurbye A, Rasch PJ, Peterson PB, et al.: Neurological syndromes in pharmacotherapy of psychosis. Acta Psychiatr Scand 1964, 40:10-27.
3. Burke RE, Fahn S, Jankovic J, et al.: Tardive dystonia: late onset and persistent dystonia caused by antipsychotic drugs. Neurology 1982, 32:1335-1346.
4. Kang UJ, Burke RE, Fahn S: Natural history and treatment of tardive dystonia. Mov Disord 1986, 1:193-208.
5. Braude WM, Barnes TRE: Late-onset akathisia - an indicant of covert dyskinesia: two case reports. Am J Psychiatry 1983, 140:611-612.
6. Little JT, Jankovic J: Tardive myoclonus. Mov Disord 1987, 2:307-312.
7. Bharucha KJ, Sethi KD: Tardive tourettism after exposure to neuroleptic therapy. Mov Disord 1995, 10:791-793.
8. Stacy M, Jankovic J: Tardive tremor. Mov Disord 1992, 7:53-57.
9. Kiriakakis V, Bhatia KP, Quinn NP, Marsden CD: The natural history of tardive dystonia. A long-term follow-up study of 107 cases. Brain 1998, 121:2053-2066.
10. Correll CU, Leucht S, Kane JM: Lower risk for tardive dyskinesia associated with second-generation antipsychotics: a systematic review of 1-year studies. Am J Psychiatry 2004, 161:414-425.
11. Tarsy D, Baldessarini RJ, Tarazi FI: Effects of newer antipsychotics on extrapyramidal function. CNS Drugs 2002, 16:23-45.
12. Jankovic J: Tardive syndromes and other drug-induced movement disorders. Clin Neuropharmacol 1995, 18:197-214.
13. Fernandez HH, Friedman JH: Classification and treatment of tardive syndromes. Neurologist 2003, 9:16-27.
14. Skidmore F, Weiner WJ, Burke R: Tardive dyskinesia variants. Drug Induced Movement Disorders. Edited by Weiner WJ, Lang A. Malden, MA: Blackwell Publishing; 2005:257-284.
15. Fahn S: Concept and classification of dystonia. In Dystonia 2, Advances in Neurology. Edited by Fahn S, Marsden CD, Calne DB. New York: Raven Press; 1988:2-8.
16. Sachdev P: Tardive blepharospasm. Mov Disord 1998, 13:947-951.
17. Levin H, Reddy R: Clozapine in the treatment of neuroleptic-induced blepharospasm: a report of 4 cases. J Clin Psychiatry 2000, 61:140-143.
18. Tan EK, Jankovic J: Tardive and idiopathic oromandibular dystonia: a clinical comparison. J Neurol Neurosurg Psychiatry 2000, 68:186-190.
19. Molho ES, Feustel PJ, Factor SA: Clinical comparison of tardive and idiopathic cervical dystonia. Mov Disord 1998, 13:486-489.
20. Brashear A, Ambrosius WT, Eckert GJ, Siemers ER: Comparison of treatment of tardive dystonia and idiopathic cervical dystonia with botulinum toxin type A. Mov Disord 1998, 13:158-161.
21. Krack P, Schneider S, Deuschl G: Geste device in tardive dystonia with retrocollis and opisthotonic posturing. Mov Disord 1998, 13:155-157.
22. Soares KVS, McGrath JJ: Vitamin E for neuroleptic-induced tardive dyskinesia. The Cochrane Database of Systematic Reviews 2001; 4.
23. Friedman JH: Clozapine treatment of psychosis in patients with tardive dystonia: Report of three cases. Mov Disord 1994, 9:321-324.
24. Wolf ME, Mosnaim AD: Improvement of axial dystonia with the administration of clozapine. Int J Clin Pharm Ther 1994, 32:282-283.
25. Trugman JM, Leadbetter R, Zalis ME, et al.: Treatment of severe axial tardive dystonia with clozapine: case report and hypothesis. Mov Disord 1994, 9:441-446.
26. Shapleske J, McKay AP, McKenna PJ: Successful treatment of tardive dystonia with clozapine and clonazepam. Br J Psych 1996, 168:516-518.
27. Lucetti C, Bellini G, Nuti A, et al.: Treatment of patients with tardive dystonia with olanzapine. Clin Neuropharmacol 2002, 25:71-74.
28. Greene P: Baclofen in the treatment of dystonia. Clin Neuropharmacol 1992, 15:276-288.
29. Dressler D, Oeljeschlager RO, Ruther E: Severe tardive dystonia: treatment with continuous intrathecal baclofen administration. Mov Disord 1997, 12:585-587.
30. Jankovic J: Botulinum toxin in clinical practice. J Neurol Neurosurg Psychiatry 2004, 75:951-957.
31. Tarsy D, Kaufman D, Sethi KD, et al.: An open-label study of botulinum toxin A for treatment of tardive dystonia. Clin Neuropharmacol 1997, 20:90-93.
32. Chatterjee A, Forrest Gordon M, Giladi N, Trosch R: Botulinum toxin in the treatment of tardive dystonia. J Clin Psychopharmacol 1997, 17:497-498.
33. Comella CL, Shannon KM, Jaglin J: Extensor truncal dystonia: successful treatment with botulinum toxin injections. Mov Disord 1998, 13:552-555.
34. Trottenberg T, Volkmann J, Deuschl G, et al.: Treatment of severe tardive dystonia with pallidal deep brain stimulation. Neurology 2005, 64:344-346.
35. Trottenberg T, Paul G, Meissner W, et al.: Pallidal and thalamic neurostimulation in severe tardive dystonia. J Neurol Neurosurg Psychiatry 2001, 70:557-559.